Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Abliva Ord Shs NEVPF

Financial Services Healthcare Asset Management Biotechnology
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.

Recent & Breaking News (GREY:NEVPF)

NeuroVive Pharmaceutical AB Year End Report January - December 2019

PR Newswire February 19, 2020

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

PR Newswire December 16, 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019

PR Newswire November 20, 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

PR Newswire August 21, 2019

Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019

PR Newswire August 20, 2019

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation

PR Newswire July 27, 2019

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

PR Newswire July 4, 2019

NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA

PR Newswire May 10, 2019

NeuroVive Pharmaceutical AB Publishes 2018 Annual Report

PR Newswire March 25, 2019

NeuroVive Receives SEK 28.2 Million in a Directed New Share Issue

PR Newswire Europe Non Regulatory March 7, 2019

NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds

PR Newswire Europe Non Regulatory February 21, 2019

NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders

PR Newswire Europe Non Regulatory November 15, 2018

NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1

PR Newswire Europe Non Regulatory October 31, 2018

NeuroVive Receives KL1333 Clinical Trial Regulatory Approval

PR Newswire October 10, 2018

NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI

PR Newswire October 4, 2018

NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan

PR Newswire September 6, 2018

NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia

PR Newswire August 28, 2018

NeuroVive Pharmaceutical AB Interim Report January - June 2018

PR Newswire August 21, 2018

NeuroVive Out-licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics

PR Newswire June 18, 2018

Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)

PR Newswire May 31, 2018